Key result
Fixed-dose combinations of verapamil/trandolapril, atenolol/chlorthalidone, and lisinopril/hydrochlorothiazide reduced sitting diastolic blood pressure compared to placebo.
Why the study?
Do fixed-dose antihypertensive combinations (verapamil/trandolapril, atenolol/chlorthalidone, lisinopril/hydrochlorothiazide) reduce blood pressure compared to placebo in patients with essential hypertension?
RCT (n=205)
Double-blind
randomly assigned
Yes
Do fixed-dose antihypertensive combinations (verapamil/trandolapril, atenolol/chlorthalidone, lisinopril/hydrochlorothiazide) reduce blood pressure compared to placebo in patients with essential hypertension?
A low-dose combination of sustained-release verapamil and trandolapril is as effective as traditional beta-blocker/diuretic or ACE-inhibitor/diuretic combinations in reducing blood pressure in essential hypertension.
Answers are grounded in this paper and cite their sources.
Supports fixed-dose combinations for BP lowering in essential hypertension; confirms comparable efficacy of verapamil/trandolapril to standard regimens.
OBJECTIVE: To compare the effects of fixed-dose preparations containing 180 mg sustained-release verapamil and 2 mg trandolapril, 100/25 mg atenolol/chlorthalidone, 20/12.5 mg lisinopril/hydrochlorothiazide and placebo in patients with essential hypertension. DESIGN: A 4-week placebo run-in period followed by a double-blind, placebo-controlled parallel group study lasting 8 weeks. SETTING: Office practices (21 centres). PATIENTS: Patients with essential hypertension (World Health Organization grades I or II); supine diastolic blood pressure 101-114 mmHg in week 4 of the run-in period; 215 patients were enrolled, of whom 205 were assigned randomly to double-blind therapy. MAIN OUTCOME MEASURES: Reduction in supine and standing blood pressures. RESULTS: All three active treatments with a single daily dose were significantly more effective than was placebo in reducing the blood pressure of seated subjects (P=0.0001). The reductions in sitting diastolic blood pressure (DBP) from baseline to the last visit with each active treatment were comparable: 13 mmHg [95% confidence interval (CI) 16-9] with sustained-release verapamil/trandolapril, 13 mmHg (16-9) with atenolol/chlorthalidone and 12 mmHg (15-8) with lisinopril/hydrochlorothiazide. Normalization of blood pressure (DBP < 90 mmHg) was observed in 48% of patients with sustained-release verapamil/trandolapril, in 46% with atenolol/chlorthalidone and in 40% with lisinopril/hydrochlorothiazide. Response rates (normalization of DBP or a reduction in DBP by > 10 mmHg) with each active treatment were 72% for sustained-release verapamil/trandolapril, 76% for atenolol/chlorthalidone and 69% for lisinopril/hydrochlorothiazide. All three active treatments were tolerated well. CONCLUSION: This study demonstrates that the low-dose combination sustained-release verapamil/trandolapril may be a suitable alternative for combinations containing a thiazide diuretic or a beta-blocker for longer term management of hypertensive patients for whom combination therapy is indicated.
No takes yet. Share an insight, caveat, or question.
Leeuw et al. (1997) conducted an RCT in essential hypertension (n=205). sustained-release verapamil/trandolapril, atenolol/chlorthalidone, and lisinopril/hydrochlorothiazide vs. placebo was evaluated on Reduction in supine and standing blood pressures (MD 13, 95% CI 9-16, p=0.0001). Fixed-dose combinations of verapamil/trandolapril, atenolol/chlorthalidone, and lisinopril/hydrochlorothiazide reduced sitting diastolic blood pressure compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: